17 results about "P2x7 receptor" patented technology

The present invention relates to chimeric antigen receptors for binding to a dysfunctional P2X7 receptor, genetically modified cells comprising such chimeric antigen receptors and uses thereof.

The present invention relates to radiolabeled molecules and related precursor molecules for the detection of immune cells expressing receptors comprising an antigen binding site and a signaling domain for binding to a P2X7 receptor of a dysfunction.

The present invention provides compounds represented by formula (I), and stereoisomers, solvates, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used as P2X7 receptor antagonists.

Described herein are compounds of formula (I), where the substituents are disclosed herein, and exhibit antagonistic and / or inhibitory activity against the P2X7 receptor. These compounds, and their pharmaceutically acceptable salts, hydrates, solvates, and compositions thereof, are suitable for use in the prevention and treatment of diseases and conditions modulated by inhibition of the P2X7 receptor.

The present invention relates to fusion proteins and their use for obtaining and isolating an enriched population of immune cells. Exemplary fusion proteins include those that comprise a dysfunctional purinergic P2X7 receptor (P2X7R) epitope portion and an Fc region of an antibody.

The present application relates to the field of chemical drugs, and discloses a P2X7 receptor antagonist. The structure of the P2X7 receptor antagonist is as shown in formula I. The present application has found that the compound shown in formula I not only has excellent antagonistic activity for the P2X7 receptor, but also has excellent metabolic stability and pharmacokinetic properties. Compared with the positive control JNJ47965567, the metabolic stability and pharmacokinetic properties of the compound of the present application are significantly improved, and the druggability is significantly better. The compound shown in formula I is used as a P2X7 receptor antagonist, and can be used to prepare a drug for treating illnesses such as inflammation and inflammation-related diseases, kidney diseases, respiratory diseases, cancer, pain, central nervous system diseases, radiation-induced brain injury, cerebral ischemia, myocardial injury, diabetes, depression, lupus erythematosus, atherosclerosis, and allergic asthma, and has broad application prospects.

To provide a method for treatment of patients suffering from a hyperinflammatory syndrome without hampering the inflammatory response of the patients or at least to a much lesser extent.SOLUTION: Provided is an antagonist of a mammalian P2X7 receptor (P2X7R) for use in the treatment of a hyperinflammatory syndrome in a mammalian patient, by primary lymph node targeted administration of the P2X7R antagonist in the patient to a concentration of the antagonist of the mammalian P2X7R in the targeted lymph nodes that is above the maximal tolerable plasma level of the antagonist in the mammal.SELECTED DRAWING: None

Use of NADPH in the preparation of a drug for treating major depression, bipolar disorder, post-stroke depression or neuroinflammation, and use of NADPH or a pharmaceutically acceptable salt thereof in the preparation of a P2X7 receptor antagonist. Research finds that NADPH inhibits the rise of an inward current in microglia caused by ATP-induced calcium influx and P2X7 receptor activation. It is indicated that NADPH can inhibit ATP-induced P2X7R activation and inflammasome activation and it is shown that NADPH can be used as a P2X7 receptor inhibitor, and can be further used for preventing or treating diseases caused by P2X7 receptor activation and inflammasome activation, wherein these diseases comprise major depression, bipolar disorder, post-stroke depression or neuroinflammation-related diseases.

The invention provides a compound as shown in a formula (I), and a stereoisomer, a solvate, a pharmaceutically acceptable salt or a prodrug thereof. The compound can be used as a P2X7 receptor antagonist.

The present invention relates to compositions for use in the treatment of chronic, persistent or hyperinflammation and to methods for the treatment of chronic, persistent or hyperinflammatory conditions both of which involve prolonged or excessive inflammation, such as those experienced post an infection, particularly a viral infection, or following an autoimmune disease. An inclusion complex of lidocaine and cyclodextrins is demonstrated to provide therapeutic benefit, both causal and symptomatic, in Long COVID patients.

Compositions, methods, and kits are provided for treating infections and cancer with metallic nanoclusters. In particular, metallic nanoclusters having a size of less than 10 nm that are conjugated to adenosine triphosphate (ATP) or an analogue thereof can be used to eradicate a cell in a growth arrest phase such as infectious bacterial or fungal cells. Such nanoclusters can also induce endoplasmic reticulum stress and inhibit growth of cancerous cells. Additionally, such metallic nanoclusters can be used to inhibit a purinergic P2X7 receptor and FtsH protease.

The present invention relates to novel 1,4-substituted piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions containing these compounds, chemical processes for preparing these compounds, and their use in the treatment or prevention of diseases associated with P2X7 receptor activity in animals, particularly humans.

The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.

The invention relates to fusion proteins and uses thereof for obtaining and isolating enriched populations of immune cells. Exemplified fusion proteins include those comprising a dysfunctional purinergic P2X7 receptor (P2X7R) epitope moiety and a Fc region of an antibody.

The present invention relates to novel 1,4-substituted piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.

The present invention relates to fusion proteins and their use for obtaining and isolating an enriched population of immune cells. Example fusion proteins include fusion proteins comprising a dysfunctional purinergic P2X7 receptor (P2X7R) epitope portion and an Fc region of an antibody.

The present invention relates to novel N-arylbenzamide derivatives of formula (I) or isotopic forms, stereoisomers or pharmaceutically acceptable salts thereof as P2X7 receptor antagonists. The invention also relates to pharmaceutical compositions comprising such compounds, chemical processes for preparing such compounds and the use of such compounds in the treatment or prevention of diseases or conditions associated with P2X7 receptor activity.